Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1376-1381

  Lepeule, Raphaël ^a   Ruppé, Etienne ^a,b   Le, Patrick ^b   Massias, Laurent ^b   Chau, Françoise ^a   Nucci, Amandine ^c   Lefort, Agnès ^a,d   Fantin, Bruno ^a,d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b BICHAT HOSPITAL   (France)

^c INSTITUT PASTEUR   (France)

^d BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE CTX M; BETA LACTAMASE CTX M 15; CARBAPENEM DERIVATIVE; CEFOXITIN; CEFTRIAXONE; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BLADDER; COLONY FORMING UNIT; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; GENE FREQUENCY; KIDNEY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; URINARY TRACT INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; BETA-LACTAMASES; BETA-LACTAMS; CARBAPENEMS; CEFOXITIN; CEFTRIAXONE; CONJUGATION, GENETIC; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; IMIPENEM; KIDNEY; MICE; MICROBIAL SENSITIVITY TESTS; MUTATION RATE; PLASMIDS; URINARY BLADDER; URINARY TRACT INFECTIONS;

EID: 84857144526     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06233-11     Document Type: Article

References (41)

1. Alder J, Clement JJ. 1993. Comparative chemotherapeutic activity of temafloxacin, cefoxitin, clindamycin, imipenem and ampicillin/sulbactam against Bacteroides fragilis in a mouse subcutaneous abscess model. J. Antimicrob. Chemother. 31:303-311. (Pubitemid 23092843)
2. Allou N, Cambau E, Massias L, Chau F, Fantin B. 2009. Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection. Antimicrob. Agents Chemother. 53:4292-4297.
3. Ananthan S, Subha A. 2005. Cefoxitin resistance mediated by loss of a porin in clinical strains of Klebsiella pneumoniae and Escherichia coli. Indian J. Med. Microbiol. 23:20-23. (Pubitemid 40347428)
4. Andes D, Craig WA. 2005. Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations. Clin. Microbiol. Infect. 11(Suppl 6):10-17. (Pubitemid 41535940)
5. Beskid G, Christenson JG, Cleeland R, DeLorenzo W, Trown PW. 1981. In vivo activity of ceftriaxone (Ro 13-9904), a new broad-spectrum semisynthetic cephalosporin. Antimicrob. Agents Chemother. 20:159-167. (Pubitemid 11015122)
6. Bin C, et al. 2006. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli. Diagn. Microbiol. Infect. Dis. 56:351-357. (Pubitemid 44854354)
7. Boyd DA, et al. 2004. Complete nucleotide sequence of a 92-kilobase plasmid harboring the CTX-M-15 extended-spectrum beta-lactamase involved in an outbreak in long-term-care facilities in Toronto, Canada. Antimicrob. Agents Chemother. 48:3758-3764. (Pubitemid 39304600)
8. Bradford PA, et al. 1997. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the loss of an outer membrane protein. Antimicrob. Agents Chemother. 41:563-569. (Pubitemid 27098404)
9. Canton R, Coque TM. 2006. The CTX-M beta-lactamase pandemic. Curr. Opin. Microbiol. 9:466-475.
10. CLSI. 2010. Performance standards for antimicrobial susceptibility testing; 20th informational supplement. CLSI M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Cuzon G, Naas T, Guibert M, Nordmann P. 2010. In vivo selection of imipenem-resistant Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-15 and plasmid-encoded DHA-1 cephalosporinase. Int. J. Antimicrob. Agents 35:265-268.
12. dos Santos KV, et al. 2007. Comparative activity of ertapenem and piperacillin tazobactam in a murine systemic infection model with Bacteroides fragilis and Escherichia coli. J. Med. Microbiol. 56:1576-1579.
13. Emery CL, Weymouth LA. 1997. Detection and clinical significance of extended-spectrum beta-lactamases in a tertiary-care medical center. J. Clin. Microbiol. 35:2061-2067. (Pubitemid 27318705)
14. European Commission. 1986. European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes, Conseil de l'Europe. Éditeur scientifique ed. Council of Europe, Strasbourg, France.
15. Garcia-Capdevila L, et al. 1997. Determination of imipenem in plasma by high-performance liquid chromatography for pharmacokinetic studies in patients. J. Chromatogr. B Biomed. Sci. Appl. 692:127-132. (Pubitemid 27208473)
16. Girlich D, Poirel L, Nordmann P. 2009. CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli. Antimicrob. Agents Chemother. 53:832-834.
17. Kucers A. 1997. The use of antibiotics: a clinical review of antibacterial, antifungal, and antiviral drugs, 5th ed. Butterworth-Heinemann, Oxford, United Kingdom.
18. Kumarasamy KK, et al. 2010. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis. 10:597-602.
19. Labat F, et al. 2005. Mutator phenotype confers advantage in Escherichia coli chronic urinary tract infection pathogenesis. FEMS Immunol. Med. Microbiol. 44:317-321. (Pubitemid 40719968)
20. Lartigue MF, Poirel L, Poyart C, Reglier-Poupet H, Nordmann P. 2007. Ertapenem resistance of Escherichia coli. Emerg. Infect. Dis. 13:315-317. (Pubitemid 46193182)
21. Lavollay M, et al. 2006. Clonal dissemination of a CTX-M-15 betalactamase-producing Escherichia coli strain in the Paris area, Tunis, and Bangui. Antimicrob. Agents Chemother. 50:2433-2438. (Pubitemid 43993183)
22. Lee CH, et al. 2007. Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of blaDHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 beta-lactamases. J. Antimicrob. Chemother. 60:410-413. (Pubitemid 47243895)
23. Lee CH, Su LH, Tang YF, Liu JW. 2006. Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates. J. Antimicrob. Chemother. 58:1074-1077.
24. Leggett JE, et al. 1989. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J. Infect. Dis. 159:281-292. (Pubitemid 19049368)
25. Livermore DM, Oakton KJ, Carter MW, Warner M. 2001. Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent betalactamases. Antimicrob. Agents Chemother. 45:2831-2837. (Pubitemid 32906679)
26. Majumdar AK, et al. 2002. Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob. Agents Chemother. 46:3506-3511. (Pubitemid 35192918)
27. Melzer M, Petersen I. 2007. Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing Escherichia coli compared to non-ESBL producing Escherichia coli. J. Infect. 55:254-259. (Pubitemid 47244918)
28. Mnif B, et al. 2010. Molecular characterization of addiction systems of plasmids encoding extended-spectrum beta-lactamases in Escherichia coli. J. Antimicrob. Chemother. 65:1599-1603.
29. Navon-Venezia S, et al. 2006. Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel. Antimicrob. Agents Chemother. 50:3098-3101. (Pubitemid 44396417)
30. Nordmann P, Cuzon G, Naas T. 2009. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis. 9:228-236.
31. Pacheco AB, et al. 1997. Random amplification of polymorphic DNA reveals serotype-specific clonal clusters among enterotoxigenic Escherichia coli strains isolated from humans. J. Clin. Microbiol. 35:1521-1525. (Pubitemid 27216824)
32. Palasubramaniam S, Muniandy S, Navaratnam P. 2009. Resistance to extended-spectrum beta-lactams by the emergence of SHV-12 and the loss of OmpK35 in Klebsiella pneumoniae and Escherichia coli in Malaysia. J. Microbiol. Immunol. Infect. 42:129-133.
33. Pangon B, et al. 1989. In vivo selection of a cephamycin-resistant, porindeficient mutant of Klebsiella pneumoniae producing a TEM-3 betalactamase. J. Infect. Dis. 159:1005-1006. (Pubitemid 19113092)
34. Pearson RD, Steigbigel RT, Davis HT, Chapman SW. 1980. Method of reliable determination of minimal lethal antibiotic concentrations. Antimicrob. Agents Chemother. 18:699-708. (Pubitemid 11164141)
35. Pitout JD. 2010. Infections with extended-spectrum beta-lactamase- producing Enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs 70:313-333.
36. Pitout JD, Laupland KB. 2008. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect. Dis. 8:159-166. (Pubitemid 351249250)
37. Ruppe E, et al. 2009. CTX-M beta-lactamases in Escherichia coli from community-acquired urinary tract infections, Cambodia. Emerg. Infect. Dis. 15:741-748.
38. Schrogie JJ, et al. 1978. Bioavailability and pharmacokinetics of cefoxitin sodium. J. Antimicrob. Chemother. 4:69-78. (Pubitemid 8403806)
39. Signs SA, Tan JS, Salstrom SJ, File TM. 1992. Pharmacokinetics of imipenem in serum and skin window fluid in healthy adults after intra-muscular or intravenous administration. Antimicrob. Agents Chemother. 36:1400-1403.
40. Solomkin JS, et al. 2010. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin. Infect. Dis. 50:133-164.
41. Suankratay C, Jutivorakool K, Jirajariyavej S. 2008. A prospective study of ceftriaxone treatment in acute pyelonephritis caused by extended-spectrum beta-lactamase-producing bacteria. J. Med. Assoc. Thai. 91: 1172-1181.